SEC Filing Summary: Cerecor Inc. (Form 8-K)
Business Context and Reporting Period
This Form 8-K was filed by Cerecor Inc. on September 27, 2018. The registrant is a Delaware corporation and an emerging growth company. The filing serves as a current report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This document is a disclosure of a corporate event rather than a financial statement.
Material Changes
No material financial changes or operational updates are detailed in the text of this filing. The report focuses solely on the disclosure of a presentation made at an industry conference.
Guidance, Outlook, and Management Commentary
On September 27, 2018, Cerecor Inc. presented at the Oppenheimer & Co. Inc. Fall Summit in New York, which focused on specialty pharmaceuticals and orphan and rare diseases. A slide show presentation from this event is attached as Exhibit 99.1. The filing explicitly states that the information in Item 7.01 and Exhibit 99.1 is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings unless expressly stated.
Key Facts for Investor Verification
- Verify the content of the attached Exhibit 99.1 (Slide Show Presentation) for specific business updates, as the 8-K text itself contains no operational data.
- Confirm that the presentation materials are not legally incorporated by reference into the company's other SEC filings.
- Note the company's status as an Emerging Growth Company that has elected not to use the extended transition period for new accounting standards.
- Review the company's principal executive office location: 400 E. Pratt Street, Suite 606, Baltimore, Maryland 21202.